KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Accounts Payables (2016 - 2025)

Gilead Sciences (GILD) has disclosed Accounts Payables for 17 consecutive years, with $715.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 14.17% year-over-year to $715.0 million, compared with a TTM value of $715.0 million through Dec 2025, down 14.17%, and an annual FY2025 reading of $715.0 million, down 14.17% over the prior year.
  • Accounts Payables was $715.0 million for Q4 2025 at Gilead Sciences, down from $808.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $905.0 million in Q4 2022 and bottomed at $537.0 million in Q2 2024.
  • Average Accounts Payables over 5 years is $662.8 million, with a median of $618.0 million recorded in 2022.
  • The sharpest move saw Accounts Payables plummeted 39.23% in 2023, then surged 54.1% in 2024.
  • Year by year, Accounts Payables stood at $705.0 million in 2021, then increased by 28.37% to $905.0 million in 2022, then tumbled by 39.23% to $550.0 million in 2023, then skyrocketed by 51.45% to $833.0 million in 2024, then dropped by 14.17% to $715.0 million in 2025.
  • Business Quant data shows Accounts Payables for GILD at $715.0 million in Q4 2025, $808.0 million in Q3 2025, and $582.0 million in Q2 2025.